Clariane SE (LTS:0OPS) Other Financing: €-344 Mil (TTM As of Dec. 2025)


LTS:0OPS Clariane SE LTS:0OPS
61 GF Score
Price €4.17
GF Value €2.46
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Clariane SE Other Financing?

Clariane SE LTS:0OPS +0.19% 61 Other Financing is €-344 Mil as of Dec. 2025. GuruFocus rates LTS:0OPS with a GF Score™ of 61/100 and a GF Value™ of €2.46 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Clariane SE's Other Financing for the six months ended in Dec. 2025 was €-193 Mil.

Clariane SE's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €-344 Mil.

Clariane SE Other Financing Historical Data

* Premium members only.

The historical data trend for Clariane SE's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clariane SE Other Financing Chart

Clariane SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.71 -214.63 -173.76 -377.39 -343.89

Clariane SE Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -152.21 -224.98 -152.42 -150.52 -193.37
LTS:0OPS
61GF Score
Clariane SE LTS:0OPS
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clariane SE Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-344 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-344 Mil mean?
Clariane SE (LTS:0OPS) has a Other Financing of €-344 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Clariane SE and its competitors.
Is Clariane SE's Other Financing too high?
Clariane SE's current Other Financing is €-344 Mil. Overall, Clariane SE has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's Other Financing compare to HCA and THC?
Clariane SE's Other Financing of €-344 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Healthcare Providers & Services company?
A good Other Financing depends on the Healthcare Providers & Services industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Clariane SE and its competitors. Clariane SE's current Other Financing is €-344 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (LTS:0OPS) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.46, compared to a current price of €4.17 — trading 69.5% above its estimated fair value. The current Other Financing is €-344 Mil. Clariane SE's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Clariane SE (LTS:0OPS), the current Other Financing is €-344 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clariane SE (LTS:0OPS) Overvalued in 2026?

Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued. The current stock price of €4.17 is trading 69.5% above its estimated GF Value™ of €2.46. GuruFocus considers Clariane SE to be Significantly Overvalued.

Key valuation signals for LTS:0OPS:

  • Other Financing: €-344 Mil
  • GF Value™: €2.46 vs. price of €4.17 (69.5% above fair value)
  • GF Score™: 61/100 with 9 warning signs

No single metric tells the full story. See the LTS:0OPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clariane SE Business Description

Address 21-25, Rue Balzac, Paris, FRA, 75008
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
61GF Score

Get the complete analysis for LTS:0OPS

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.17
Price
€2.46
GF Value